American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HHV-6 in the lymphoma microenvironment: Both chicken and egg?
    Meeting Abstract

    Crane, G. M.; Tychinin, D.; Karelin, A.; Cherdintsev, A.; Kudryashova, O.; Egorov, E.; Degryse, S.; Kotlov, N.; Bagaev, A.; Casano, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Normalization of the immune microenvironment during lenalidomide maintenance is associated with sustained MRD negativity in patients with multiple myeloma
    Meeting Abstract

    Coffey, D. G.; Maura, F.; Gonzalez-Kozlova, E.; Diaz-Mejia, J.; Luo, P.; Zhang, Y.; Xu, Y.; Warren, E. H.; Smith, E. L.; Cho, H. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impaired RAS proteolysis drives clonal hematopoietic transformation
    Meeting Abstract

    Chen, S.; Vedula, R. S.; Castel, P.; Cuevas Navarro, A.; Hogg, S. J.; Wang, E.; Mi, X.; Benbarche, S.; Knorr, K.; Kim, W. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of autologous hematopoietic cell transplant (HCT) followed by dendritic cell/myeloma fusion vaccine with lenalidomide maintenance in increasing multiple myeloma (MM) immunity (BMT CTN 1401)
    Meeting Abstract

    Chung, D. J.; Shah, N.; Stroopinsky, D.; Wu, J.; Bisharat, L.; Callander, N. S.; Logan, B. R.; Anderson, K. C.; Chodon, T.; Mohan, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Non-relapse mortality in TP53-mutated MDS/AML - A multi-center collaborative study
    Meeting Abstract

    Byrne, M. T.; Kurian, T. J.; Patel, D. A.; Tamari, R.; Hong, S.; Abdelhakim, H.; Klein, V.; Rojas, P.; Madhavan, R.; Kent, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • RNA binding protein SYNCRIP is required for the low-output HSC by sustaining proteome quality
    Meeting Abstract

    Herrejon Chavez, F.; Cifani, P.; Pine, A.; Chu, K. L.; Barin, E.; Schurer, A.; Luo, H.; Nguyen, D. T. T.; Kentsis, A.; Leslie, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Synergism between CAR-T cells and a personalized tumor vaccine in hematological malignances
    Meeting Abstract

    Cheloni, G.; Capelletti, M.; Torres, D.; Bindal, P.; Liegel, J. J.; Stroopinsky, D.; Bisharat, L.; Rahimian, M.; Yoo, S. Y.; Hauser, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥ 2 prior lines of therapy: Pivotal results from a phase I/II study
    Meeting Abstract

    Budde, L. E.; Sehn, L. H.; Matasar, M. J.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of choice of platinum-based salvage therapy on CNS relapse in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Buege, M. J.; Dao, P.; Dematteo, R. G.; LeVoir, A.; Pak, T.; Batlevi, C. L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of entospletinib in combination with intensive induction and consolidation chemotherapy in adults with newly diagnosed nucleophosmin 1-mutated acute myeloid leukemia
    Meeting Abstract

    Byrd, J. C.; Cortes, J. E.; Minden, M. D.; Oellerich, T.; Stein, E. M.; Elder, J.; Kumar, P.; Bray, G.; DiMartino, J.; Stock, W.
    Blood (2021)

    Fulltext@MSK | Save